Russian antitrust regulator initiates case against manufacturers of generics Pfizer’s Eliquis
Russian antitrust regulator the Federal Antimonopoly Service (FAS) has opened a case against the Russian subsidiary of Israel’s Teva Pharmaceuticals (NYSE: TEVA) and the Russian company Grotex for the launch of generic versions of the antithrombotic drug Eliquis prior to expiration of patent for its active ingredient – apixaban.
The patent is owned by Pfizer Innovations, which filed a complaint with the FAS. According to Pfizer, Teva and Grotex launched their generic versions of Eliquis onto the market before the patent expired. A FAS commission will review the companies' actions for compliance with the Law on Protection of Competition.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
| Headless Content Management with Blaze